Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selicrelumab - Roche

Drug Profile

Selicrelumab - Roche

Alternative Names: RG-7876; RO-7009789

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Abramson Cancer Center of the University of Pennsylvania; Lymphoma Academic Research Organisation; Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pancreatic cancer; Solid tumours
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 26 Jul 2021 The Lymphoma Academic Research Organisation and Roche terminates phase I trial in Non-Hodgkin's lymphoma (Combination therapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in France (Intratumoural) (NCT03892525)
  • 23 Jul 2021 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in France (Intratumoural)
  • 28 Apr 2021 No recent reports of development identified for phase-I development in Pancreatic-cancer in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top